On the morning of July 31, Baiyunshan Hutchison Whampoa and Brunei Pharmaceuticals (Shantou) Co., Ltd., jointly established by Guangzhou Baiyunshan Hutchison Whampoa Co., Ltd. (with an investment of more than 56 million yuan) and Guangdong Brunei Pharmaceuticals, was officially inaugurated. This is the first project settled after Guangzhou Pharmaceutical Group signed a strategic cooperation agreement with Shantou government in 2013, which is also a bridgehead project of Guangzhou Pharmaceutical Group＇s "Great Southern Pharmaceuticals" sector in the eastern Guangdong region.

The new joint venture will focus on planning of more than 30 varieties, in particular the two exclusive varieties in China, through the research resources and strength of Baiyunshan Hutchison Whampoa, to quickly upgrade its technology content, striving to be a high-tech enterprise with independent creativity and a mid-sized pharmaceutical company with core competitiveness, and becoming a leading pharmaceutical enterprise in Shantou.
 

Source:Shantou Daily, Aug 1, 2015

　　7月31日上午，由广州白云山和记黄埔有限公司投资5600多万元与广东莱达制药共同成立的白云山和记黄埔莱达制药(汕头)有限公司正式揭牌成立。这是2013年广药集团与市政府签订战略合作协议之后首个落地的项目，也是广药集团“大南药”板块在粤东地区的桥头堡项目。
　　新合资公司将对30多个品种尤其是两个全国独家品种进行重点规划，通过白云山和黄的科研资源和实力，快速提升企业科技含量，力争成为富有自主创新能力的高新技术企业和具有核心竞争力的中型医药企业，成为汕头市制药的龙头企业。

来源：汕头日报2015-8-1